Expression and clinical significance of CD44V5 and CD44V6 in resectable colorectal cancer

Vizoso, F; Fernández, José Carlos Fernández; Corte, M.D.; Bongera, Miguel; Gava, Rodrigo; Allende, M.T.; García-Muñiz, José L.; García-Morán, M

doi:10.1007/s00432-004-0596-1

Cited by 15 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of CD44 standard, v2, v3, v6, and v9 have been demonstrated in CRC patients (36, 51, 53, 55, 57). However, there are still controversies about the prognostic role of CD44s and CD44v in patients of CRC.…”

Section: Discussionmentioning

confidence: 99%

The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

Background: CD44 is widely used as a putative cancer stem cells (CSCs) marker for colorectal cancer (CRC). However, the prognostic role of CD44 in CRC remains controversial. Methods: We performed a systematic review and meta-analysis to evaluate the association of various CD44 isoforms and overall survival (OS) and clinicopathological features of CRC patients. Results: A total of 48 studies were included in the meta-analysis. Total CD44 isoforms overexpression was significantly correlated with worse OS of patients with CRC (HR = 1.32, 95% CI = 1.08–1.61, P = 0.007). In a stratified analysis, a higher level of either CD44v6 or CD44v2 had an unfavorable impact on OS (HR CD44v6 = 1.50, 95% CI = 1.10–2.14, P = 0.010; HR CD44v2 = 2.93, 95% CI = 1.49–5.77, P = 0.002). Additionally, CD44 was shown to be associated with some clinicopathological features, such as lymph node metastasis (OR CD44 = 1.56, 95% CI = 1.01–2.41, P = 0.044; OR CD44v6 = 1.97, 95% CI = 1.19–3.26, P = 0.008; OR Total CD44 isoforms = 1.57, 95% CI = 1.15–2.14, P = 0.004), distant metastasis (OR CD44 = 2.90, 95% CI = 1.08–7.83, P = 0.035; OR Total CD44 isoforms = 1.89, 95% CI = 1.02–3.53, P = 0.044). Moreover, a high level of CD44 showed a possible correlation with poor differentiation (OR Total CD44 isoforms = 1.44, 95% CI = 1.00–2.08, P = 0.051), elevated level of CD44v6 tend to be correlated with tumor size (OR = 1.71, 95% CI = 0.99–2.96, P = 0.056). Conclusions: This meta-analysis demonstrated that CD44 overexpression might be an unfavorable prognostic factor for CRC patients and could be used to predict poor differentiation, lymph node metastasis and distant metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…CD44 variant 6 (CD44v6) expression correlates with poor prognosis [110–112]. However, loss of CD44 significantly correlates with poor survival when associated with a corresponding loss in E-cadherin, especially in Stage II CRC, suggesting that CD44 and E-cadherin may have an inter-dependent role in suppressing invasion and metastasis [113].…”

Section: Cancer Cellsmentioning

confidence: 99%

Cell Surface Markers in Colorectal Cancer Prognosis

Belov

Zhou

Christopherson

2010

IJMS

View full text Add to dashboard Cite

The classification of colorectal cancers (CRC) is currently based largely on histologically determined tumour characteristics, such as differentiation status and tumour stage, i.e., depth of tumour invasion, involvement of regional lymph nodes and the occurrence of metastatic spread to other organs. These are the conventional prognostic factors for patient survival and often determine the requirement for adjuvant therapy after surgical resection of the primary tumour. However, patients with the same CRC stage can have very different disease-related outcomes. For some, surgical removal of early-stage tumours leads to full recovery, while for others, disease recurrence and metastasis may occur regardless of adjuvant therapy. It is therefore important to understand the molecular processes that lead to disease progression and metastasis and to find more reliable prognostic markers and novel targets for therapy. This review focuses on cell surface proteins that correlate with tumour progression, metastasis and patient outcome, and discusses some of the challenges in finding prognostic protein markers in CRC.

show abstract

“…The modified expression of CD44v6 in malignant tumors could affect the cellular adhesion, facilitate the tumor progression, and favor metastasis 16,17. Several studies have been carried out to clarify the role of CD44v6 in different human neoplasms 18–20. However, so far, there are no studies correlating the mRNA expression of the CD44v6 gene in pancreatic cancer patients.…”

Section: Discussionmentioning

confidence: 99%

The establishment of the duplex real‐time RT‐PCR assay for the detection of CD44v6 in pancreatic cancer patients and clinical application

Zhou

Chiu

Qin

et al. 2012

Biotech and App Biochem

View full text Add to dashboard Cite

Cell adhesion molecule CD44v6 has been found to be associated with the progression and metastasis of numerous cancers. In this study, a novel duplex real-time quantitative reverse-transcription PCR (qRT-PCR) assay was developed to quantitatively detect the CD44v6 gene expression in pancreatic cancer patients. The primers and probes of CD44v6 and β-actin genes were designed and standard curve of the duplex qRT-PCR was constructed by optimizing the reaction conditions. The specificity and reproducibility of this assay were satisfactory and the detection limit was 100 copies, which was 10 times more sensitive than the conventional RT-PCR assay. This assay was also used to detect the expression levels of CD44v6 messenger RNA in peripheral blood mononuclear cell in 37 pancreatic cancer patients and 12 healthy people. The results showed that 37 clinical samples were tested positive by the duplex qRT-PCR compared with only 30 by the conventional RT-PCR. The levels of CD44v6 expression showed significant correlation with sex, tumor size, tumor differentiation, clinical stage, lymph node, and liver metastasis (P < 0.05). Compared with the control group, CD44v6 levels in patients prior and 10 days post cryosurgery were significantly increased (P < 0.05) but had no significant change in those 1 month post cryosurgery (P > 0.05). The duplex qRT-PCR assay may provide a useful tool for the evaluation of prognosis and curative effect of pancreatic cancer.

show abstract

Expression and clinical significance of CD44V5 and CD44V6 in resectable colorectal cancer

Abstract: The results of this study suggest a role of CD44v5 and CD44v6 in colorectal cancer progression. Membranous CD44v levels in primary tumors, measured by immunoenzymatic assay, may contribute to a more precise prognostic estimation in patients with resectable colorectal cancer.

Cited by 15 publications

References 39 publications

The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis

The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis

Cell Surface Markers in Colorectal Cancer Prognosis

The establishment of the duplex real‐time RT‐PCR assay for the detection of CD44v6 in pancreatic cancer patients and clinical application

Contact Info

Product

Resources

About